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ABSTRACT The metabolism of the receptor for epidermal growth factor (EGF) has been
measured by labeling the receptor in vivo with radioactive amino acid precursors and then
determining, by immunoprecipitation with specific anti-EGF receptor antisera, the rate of
degradation of the receptor when the cells are placed in a nonradioactive medium. In human
fibroblasts the rate of EGF receptor degradation (t1i2 = 10.1 h) was faster than the rate of
degradation of total cell protein . When EGF was added to the nonradioactive medium, the
half-life of prelabeled receptor was decreased to 1 .2 h in human fibroblasts. These data
demonstrate by direct analysis of receptor protein that during "down regulation" the EGF
receptor is rapidly degraded. Enhanced receptor degradation was observed 5-10 min after
the addition of EGF. The EGF-induced degradation of the receptor was blocked by methyla-
mine, chloroquine, iodoacetate, or incubation at 25°C. We have also shown that EGF-induced
down regulation in human fibroblasts results in a decrease in the total amount of EGF receptor
protein present .
The amount of EGF receptor protein has been quantitated by radiolabeling cellular protein
and immunoprecipitation of the receptor. The EGF receptor constitutes ^-0.0035% of the
cellular protein in human fibroblasts .
Epidermal growth factor (EGF)' is a low molecular weight
polypeptide that elicits mitogenic and nonmitogenic responses
in a variety of cell types (reviewed in references 1 and 2). A
specific membrane receptor for EGF has been identifiedand
purified (3-5). The receptor is a 170,000-dalton glycoprotein
having a single polypeptide chain. In addition to a binding
site for EGF, the receptor has intrinsic protein kinase activity
(5, 6) that is tyrosine specific (7) and activated by the binding
of EGF (8). The protein kinase characteristics of the EGF
receptor are similar to properties of protein kinase activities
possessed by (a) receptors for other hormones that modulate
cell growth, such as platelet-derived growth factor (9) and
insulin (10), and (b) certain viral transforming proteins that
are also membrane localized (11).
The binding of EGF to its receptors on the surface of cells
produces, with continued incubation at 37°C, a decrease in
the binding capacity of the cells for '25I-EGF (12). This
'Abbreviation used in this paper: EGF, epidermal growth factor.
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phenomenon has been observed for several polypeptide hor-
mone-receptor systems and is referred to as "down regula-
tion." Studies of EGF-induced down regulation have em-
ployed chemical (12) or morphological (13-17) techniques to
determine the fate of cell-bound EGF labeled with ' 251-,
fluorescein, or ferritin. These studies have demonstrated that
immediately after the formation of EGF-receptor complexes
on the cell surface, the labeled ligand is internalized with the
formation of endocytotic vesicles containing the labeled lig-
and in the vesicle lumen. The ultimate fate of internalized
EGF is degradation within lysosomes. The fate ofthe occupied
receptor during these events has been examined only by
indirect methodologies (12, 17-22).
To directly and quantitatively determine the fate of the
EGF receptor during EGF-induced down regulation, we have
employed an immunochemical approach that has been shown
in previous studies of enzyme turnover to yield the least
equivocal data (23). We show that in normal human fibro-
blasts EGF specifically and rapidly acceleratesthe degradation
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to that involved in the degradation of internalized EGF.
MATERIALS AND METHODS
Cell Culture:
￿
Cultures ofhuman foreskin fibroblasts (3) were prepared
essentially as previously described. The cells were cultured in 60-mm tissue
culture dishes (Falcon Labware, Oxnard, CA) and complete growth medium
consisting of Dulbecco's modified Eagle's medium (DMEM; Gibco Laborato-
ries, Grand Island, NY)supplemented with 10% calfserum (Flow Laboratories,
Inc., McLean, VA), 20 mM HEPES (Calbiochem-Behring Corp., San Diego,
CA) pH 7.5, and Garamycin (M. A. Bioproducts, Walkersville, Maryland). Cell
numbers were determined by electronic counting (Coulter Instruments, Inc.,
Hialeah, CA).
Metabolic Labeling and Solubilization of Intact Cells:
￿
slightly
subconfluent (--5 x l05 cells/dish) fibroblasts in 60-mm dishes were metabol-
ically labeled by incubating the cells for 3 d in complete growth medium
containing 33 pCi/ml t.-['SS]methionine (Amersham Corp., Arlington Heights,
IL). During this period the cell number doubled.
To prepare labeled cells for immunoprecipitation ofthe EGF receptor, the
cells were washed three times with cold phosphate buffered saline and solubi-
lized for 20 min at room temperature in RIPA buffer (10 mM Tris pH 8.5,
0.15 M NaCl, I mM EDTA, 1 % Triton X-100, 1% sodium deoxycholate, 0.1%
sodium dodecyl sulfate, and 200 Kallikrein International Units (KIU)/ml
Aprotinin). I ml of RIPA buffer was added for each milligram of cell protein
in the culture dish. Insoluble materialwasremovedbycentrifugationat 140,000
g for 1 h. Approximately 10-15% of the total ["S]methionine labeled cellular
material remained in the pellet. The EGF-receptor was not detected in this
pellet. Solubilized supernatants were either immediately subjected to immu-
noprecipitation or were frozen in dry ice-ethanol and stored at -70°C for later
analysis.
Immunoprecipitation, Electrophoresis, and Fluorogra-
phy:
￿
Solubilized cell extractswere centrifuged (8,000g, 5 min) ifpreviously
frozen. The immunoprecipitation was initiated by the addition of 2 Al anti-
EGF receptor antiserum (#451) per ml of solubilized extract containing 1 mg
protein. After incubation at room temperature for l h, 20-40 u1 of a 10%
suspension of fixed Staphylococcus aureus cells (Immunoprecipitin, Bethesda
Research Laboratories, Maryland) per wl of antiserum was added and the
incubation continued for 15 min. The immune complexes were precipitated
by centrifugation for I min at 8,000 g and the pellets were washed four times
with I ml RIPA buffer. In all experiments replicate samples were processed in
an identical manner with nonimmune rabbit serum.
The immunoprecipitated samples and molecular weight markers (BRL)
were prepared for electrophoresis by boiling for 5 min in Laemmli buffer (24).
The samples were electrophoresed on 7.5% acrylamide sodium dodecyl sulfate
gels (24) and radioactivity in the gel was detected by fluorography (25).
Preflashed Kodak X-Omat AR film was exposed for an appropriate time to the
gel at -70°C. Under these conditions, there was a linear relationship between
the amount ofradioactivity in each protein band and the intensity ofits image
on the film (25). This was determined experimentally by employing dilutions
ofastandard radioactive markerprotein. Dilutions ofthe radioactive molecular
weight markers (BRL) were usually included in each gel to ascertain the true
linearity of the assay. The developed films were densitometrically scanned with
a Gilford spectrophotometer and gel scanner and the tracings corresponding to
the EGF receptor location in the gel were cut out and weighed as a relative
measure ofthe amount ofradiolabeled receptor present.
Quantitation of Radioactivity from Sliced Polyacrylamide
Gels:
￿
To determine the absolute amount of radioactivity present in the
EGF receptor band, the gel was fixed, stained, and destained as previously
described (4). After soaking in water for 1 h, the gel was sliced into 1-mm
sections using an electric gel slicer (model 195, Bio-Rad Laboratories, Rich-
mond, CA). Each slice was placed in a scintillation vial (Fisher Scientific Co.,
Pittsburgh, PA) and crushed with a glass rod. The radioactivity in each gel slice
was eluted by adding 300 wl Soluene (Packard Instrument Co., Inc., Downers
Grove, IL), incubating the closed vials for I h at 25°C, and then adding 10 ml
Omnifluor (New England Nuclear, Boston, MA) and incubating the vials at
37°C for 24 h. The radioactivity in each slice was determined with a Beckman
LS-3133P scintillation spectrometer (Beckman Instruments, Inc., Palo Alto,
CA).
Protein Determinations:
￿
Total cell protein was quantitated in rep-
licate dishes not containing radioisotope by the micro-Biuret method of Goa
(1953). Radioactivity incorporated into total cell protein was determined by
heating an aliquot of the cell extract to 90°C for 5 min to eliminate tRNA-
aminoacyl complexes. Carrier protein (200 kg -y-globulin) was added to the
sample and the protein was precipitated by incubation in 10% trichloroacetic
acid overnight at 0°C. The precipitates were collected on glass fiber filters
(Whatman Laboratory Products, Inc., Clifton, NJ), washed with ice cold 5%
trichloroacetic acid, 95% ethanol, and acetone before drying at 60°C for 30
min. Subsequently, the filters were incubated for 30 min at 50°C afterwetting
them with 50 kl water and 300 Kl Soluene. Omnifluor scintillation fluid was
added and radioactivity was measured by scintillation counting. From these
determinations the specific activity ofradiolabeled cell protein was calculated
as counts per minute per microgram of protein.
Materials:
￿
EGF, isolated from the mouse submaxillary gland as de-
scribed by Savage and Cohen (1972), was kindly provided by Stanley Cohen,
Vanderbilt University. Fibroblast growth factor was a generous gift of Denis
Gospodarowicz, University of California at San Francisco and platelet-derived
growth factor was donated by Russell Ross, University of Washington, Seattle.
Bovineinsulin, methylamine, chloroquine, and Aprotinin were purchased from
Sigma Chemical Co. (St. Louis, MO). Iodoacetic acid was a product ofEastman
Kodak and was recrystalized with ethanol. Rabbit antisera to the affinity-
purified EGF-receptor from A-431 cells were prepared and characterized as
described previously (26).
RESULTS
Immunoprecipitation and Quantitation of
Labeled EGF Receptors
Before examining the metabolism of the EGF receptor,
experimental procedureswere adjusted to provide conditions
for maximal immunoprecipitation of the EGF-receptor from
solubilized fibroblastextracts. A ratioof 1 ul ofantiserum per
1 mg total cell protein was determined to be necessary for
immunoprecipitation of a maximal amount of EGF receptor
protein under the conditions employed. The data in Fig. 1
show that maximal immunoprecipitation ofthe EGF receptor
was obtained. In this experiment the immunoprecipitates
were electrophoresed on SDS gels which were then sliced and
counted. The region of gel surrounding the position of the
EGF receptor at 170,000 daltons is shown. Fig. 1 A demon-
strates the profile of the receptor precipitated from human
fibroblasts that had been metabolically labeled with [35S]-
methionine. Fig. 1 B showsthat when the supernatant solution
from the initial immunoprecipitate was reprecipitated, addi-
tional receptor was not precipitated. Fig. 1 C demonstrates
that no significant amount of radioactivity at the 170,000-
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FIGURE 1
￿
Quantitative immunoprecipitation of the EGF receptor.
Fibroblasts were metabolically labeled with ['SS]methionine and
solubilized as described in Materials and Methods. The EGF recep-
torwas precipitated from 1 mg fibroblast extract using2 PI antiserum
and 40 pl immunoprecipitin. Immunoprecipitation, electrophoresis,
gel slicing, and elution of radioactivity were performed as described
in Materials and Methods. The panels show the radioactivity from
gel slices in the region between the molecular weight markers
myosin (200,000 daltons) and ß-galactosidase (117,000 daltons).
The EGF-receptor has an Mr = 170,000. A shows the radioactivity
precipitated from solubilized fibroblasts by antireceptor serum
#451, whereas C shows the results obtained with normal rabbit
serum . B shows a reimmunoprecipitation of the supernatant solu-
tion derived from the immunoprecipitation shown in A.
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with normal serum . To ensure complete immunoprecipita-
tion, at least a twofold excess of antiserum was used in the
following experiments. Also a twofold excess of 10% wt/vol
fixed S . aureus cells was used to completely precipitate anti-
gen-antibody complexes .
To determine the abundance of EGF receptor protein in
human fbroblasts an experiment similar to that shown in
Fig. 1 was performed . Based on the radioactivity present in
the 170,000-dalton EGF receptor band and the specific activ-
ity (counts per microgram cell protein) of the original cell
extract, we calculate that the EGF receptor comprises
-0.0035% ofthe total cell protein inhuman fibroblasts . Since
a protein may contain a disproportionate amount of methi-
onine, we repeated this experiment using a mixture of eight
different '°C-labeled amino acids (New England Nuclear) .
The results were not substantially different from those cited
above, suggesting that the receptor contains an average num-
ber of methionine residues.
Metabolism of the EGF Receptor in Fibroblasts
Sincehuman fibroblasts respond mitogenically to EGF and
the down regulation of EGF receptors by EGF has been
extensively characterized, we have investigated receptor me-
tabolism in these cells. Cell protein was radiolabeled by in-
cubating the cells in growth medium containing [35S]methio-
nine . The effect of EGF on the degradation of the EGF
receptor was then determined by quantitating the amount of
radioactive receptor remaining during a "chase" incubation
in nonradioactive medium . The results in Fig. 2 demonstrate
the difference in the amount of labeled receptor remaining
during an 8 h chase in the absence or presence ofEGF. The
data demonstrate that there is a slight decrease in the amount
of immunoprecipitable labeled receptor from cells incubated
in the absence ofEGF (lane B) compared with the amount of
receptor present at the start of the chase (lane A) . Lane C
shows the amount of receptor present when EGF was added
with the chase medium . Densitometric scanning of the fluo-
rograms indicated that after the 8-h chase, the EGF-treated
cultures contained 14% of the receptor level present in the
cells incubated in the chase medium without EGF. Degrada-
tion products of the receptor were not detectable in cultures
incubated either in the presence or absence of EGF . In con-
trast to the accelerated degradation of the EGF receptor in
the presence of EGF, the growth factor had no detectable
influence on the degradation of other cellular proteins (lanes
D-F).
A quantitative analysis ofEGF receptor turnover was begun
by determining the half-life of the receptor under normal
culture conditions, i.e., in the absence of added EGF . The
data presented in Fig . 3 show that the basal half-life of the
EGF receptor is -10 .1 h, whereas the half-life of total fibro-
blast protein is about 51 h . Similar values were obtained when
a mixture of ' °C-labeled amino acids was used instead of
['SS]methionine to label the cells . The linearity of a semilog
plot of the degradation curves indicates that the turnover of
both the EGF receptor and total cell proteins can be described
by a first-order function . Several groups (27-29) have re-
ported, based on measurement of ' z5I-EGF binding capacity,
a shorter half-life (<6 h) of the EGF receptor when cells are
incubated with cycloheximide . Other assessments ofthe decay
ofEGF receptor activity during incubation in the presence of
other macromolecular synthesis inhibitors, such as histidinol
1050
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FIGURE 2
￿
Effect of EGF on the degradation of the EGF receptor in
fibroblasts . Fibroblasts were metabolically labeled with ["S]methi-
onine as described in Materials and Methods . To begin the chase
the cell monolayers were washed three times with Hanks' balanced
salt solution and the medium was replaced with DME-containing
0.1% BSA and 600 fag/ml unlabeled L-methionine plus EGF as
indicated, and the cells were incubated for 8 h at 37°C . Solubili-
zation of the cells, immunoprecipitation, electrophoresis, and fluo-
rography were performed as described in Materials and Methods .
Immunoprecipitations of the EGF-receptor are shown in lanes A-C
and 5 -kg aliquots of the solubilized cells are shown in lanes D-F.
Lanes A and D, no chase; lanes 8 and E, 8-h chase in medium
without EGF; lanes C and F, 8-h chase in medium containing 10 ng/
ml EGF . Values at right equal the molecular weight x 103 .
(30) or Actinomycin D (28), have indicated half-life values of
-15 h . Therefore, we have measured the half-life of EGF
receptor protein in the presence ofcycloheximide . The results
(data not presented) showed that the half-life of the EGF
receptor is increased in the presence of cycloheximide to -20
h . The capacity of protein synthesis inhibitors to decrease the
rate ofprotein degradation has been observed in other systems
(23) .
The influence ofEGF on the extent and kinetics ofreceptor
degradation is shown in Fig . 4 . Within 5-10 min EGF pro-
duced a decrease in theamount oflabeled receptor remaining
in the cells. A semilog plot ofthe data shows first-order decay
of the receptor in control cells and a biphasic decay of the
receptor in EGF-treated cells . The half-life of the EGF recep-
tor in control cells in this experiment was determined to be
9 .1 h. In the EGF-treated cells, the half-life of the receptor
during the first 2 h following the addition ofEGF was calcu-
lated to be 1 .1 h and after 2 h the half-life was 5.3 h . The
biphasic decay that was observed in the EGF-treated cells isZ
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FIGURE 3
￿
Comparison of turnover rates of the EGF receptor and
total cellular proteins in fibroblasts. Fibroblasts were labeled with
[ssS]methionine as described in Materials and Methods. To begin
the chase the cell monolayers were washed three times with Hanks'
balanced salt solution and the medium was replaced with complete
growth medium containing 600,ug/ml methionine. At the indicated
times cultures were solubilized as previously described and assayed
for radioactivity present in total trichloroacetic acid precipitable
protein and the EGF receptor. Solubilization of the cells, immuno-
precipitations, electrophoresis, fluorography, trichloroacetic acid
precipitation of labeled protein, and chemical protein determina-
tions were performed as described in Materials and Methods. ",
log of the radioactivity (counts per minute) present in trichloroacetic
acid-precipitable total cell protein. ", log of the area under the
densitometrically scanned receptor peak.
FIGURE 4
￿
Effect of EGF or the kinetics of EGF receptor degradation
in human fibroblasts. Fibroblasts were labeled with [3sS]methionine
as described in Materials and Methods. The cell monolayers were
washed three times with Hanks' balanced salt solution and the
medium was replaced with Dulbecco's Modified Eagle's Medium
containing 0.1% BSA and 600 gg/ml methionine, plus 10 ng/ml EGF
where indicated. At the indicated times, cells incubated in the
chase medium in absence (") or presence of EGF (/) were solubi-
lized and assayed for the amount of radioactive EGF receptor
remaining as described in Materials and Methods.
probably the result of at least two independent events, the
EGF-induced accelerated rate of receptor degradation and the
basal rate of receptor degradation, which occur simultane-
ously. A biphasic decay of Fc receptors during receptor-
mediated phagocytosis in macrophages likewise has been ob-
served (31). No accelerated loss of EGF receptors was observed
when cells were incubated with other mitogens such as fibro-
blast growth factor, platelet-derived growth factor, or insulin.
The percentage of labeled EGF-receptors degraded depended
on the concentration of EGF in the medium. Following an 8
h-chase, cultures treated with EGF at 0.3, 1.0, 3, and 10 ng/
ml contained, respectively, 56, 44, 14, and 9% ofthe amount
of radiolabeled EGF receptor protein present in a control
culture not exposed to the growth factor.
An alternative explanation for the observed increase in
receptor degradation in the presence ofEGF is that the growth
factor decreases the reutilization of [35S]methionine derived
from protein turnover. This explanation is unlikely, as the
rate ofdegradation of total cell protein in these experiments
was unaffected by the presence of EGF. Alternatively, an
apparent loss of receptor protein in EGF-treated cells could
be obtained if antibody recognition of the receptor was af-
fected by the binding of EGF. Control experiments however,
show that this is not the case. For example, after incubation
of cells with EGF in the presence of inhibitors that block
receptor degradation but not EGF binding, the receptor was
completely precipitable (Table I). Likewise, when cells were
incubated with EGF at 5°C, the receptor remained fully
precipitable.
The preceding experiments demonstrate that EGF causes a
rapid and extensive loss of prelabeled EGF receptors. Down
regulation, however, implies a net decrease in the total num-
ber of EGF receptors. The following experiment was per-
formed to determine whether EGF does, in fact, produce a
net decrease in the total EGF receptor population. Cells were
prelabeled with [35S]methionine, EGF was added to several
cultures without removing the radioactive precursor, and 24
h later the amount of EGF receptor remaining was deter-
mined. The results shown in Fig. 5 demonstrate that com-
paredwith a parallel culture incubated in the absence ofEGF,
the growth factor-treated cultures showed decreases of 25 and
84% (1 and 10 ng EGF/ml, respectively) in the totalamount
of receptor present. Since the label was present throughout
the experiment, these decreases represent net decreases in the
total EGF receptor population based on immunoprecipitable
receptor protein. Similar quantitative reductionsin EGFbind-
TABLE I
Influence of Inhibitors on Degradation of the EGF Receptor
during Down Regulation in Fibroblasts
EGF
Experi-
￿
receptor
ment no.
￿
Additions
￿
level*
Human fibroblasts were metabolically labeled with ['SS]methionine as de-
scribed in Materials and Methods. The medium was replaced with nonra-
dioactive DME containing 600jug/ml methionine and 0.1% BSA. The inhib-
itors were added at the indicated concentrations and the cultures were
incubated for 1 h at 37*C (or 25°C where indicated). Down regulation was
then initiated by the addition of EGF (10 ng/ml) to the indicated cultures
and the incubation at 37°C (or 25*C as shown) was continued for 2 h. The
amount of labeled receptor was then determined as described in Materials
and Methods.
* Values represent percent of untreated control.
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105 1
1 None 100
EGF (10 ng/ml) 13
Methylamine (10 mM) + EGF 103
lodoacetate (0.1 mM) + EG F 39
Monensin (20 juM) + EGF 71
25*C + EGF 133
2 None 100
EGF (10 ng/ml) 29
Chloroquine (0.1 mM) + EGF 105
lodoacetate (1 mM) + EGF 99
Colcemid (0.5,uM) + EGF 50FIGURE 5
￿
Changes in total EGF receptor level in human fibroblasts
following down regulation by EGF . Fibroblasts were metabolically
labeled with ("Slmethionine for 3 d as described in Materials and
Methods . Without removing the radioactive medium separate cul-
tures received no EGF (lanes A, B, and E), 1 ng per ml EGF (lanes C
and F), or 10 ng per ml EGF (lanes D and G) and the incubation was
continued for 24 h . The cultures were then solubilized and the
amount of radiolabeled EGF receptor present in each culture was
determined by immunoprecipitation (lanes A-D) as described in
Materials and Methods. The precipitation in lane A was performed
with normal rabbit serum . Aliquots (5 jI) of the total cellular protein
are shown in lanes E-G. Values at right equal the molecular weight
x 103.
ing capacity were obtained in human fibroblasts incubated
with or without EGF as described in Fig. 5, washed with low
pH buffer to remove surface-bound ligand, and incubated
with 'a5í-EGF (10 ng/ml) for 3 h at 4°C (data not shown) .
Inhibitors of Receptor Degradation
The results shown in Table I demonstrate the effect of
several types ofinhibitors on the EGF-stimulated degradation
of the EGF receptor. Inhibition of receptor degradation was
achieved by general inhibitors of lysosome activity, chloro-
quine, or methylamine (12), and by agents that block intra-
cellular vesicle traffic, monensin (40) and reduced tempera-
ture, i.e ., 25°C (41) . In cultures treated with methylamine, but
not chloroquine, we have consistently noted the presence of
a 150,000-dalton receptor band . It is not clear whether this is
a natural degradation product ofthe receptor or whether it is
induced by the presence of inhibitors . Iodoacetate was a
potent inhibitor ofreceptor degradation and may suggest the
participation of sulfhydryl proteases in receptor turnover .
Interestingly, two groups (32, 33) have described an iodoace-
tate-sensitive protease in cell extracts that converts the native
170,000-dalton EGF receptor to a 150,000-dalton species .
Control experiments, in which we used the low pH-wash
procedure ofAscoli (34) to differentiate surface and internal-
ized ' 25I-EGF, have demonstrated that iodoacetate does not
052
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block the binding or internalization of ' 25I-EGF-receptor com-
plexes (data not shown) .
DISCUSSION
We have directly quantitated the levels of EGF receptor
protein in cultured human cells-normal diploid skin fibro-
blasts . We calculate from the relative abundance of EGF
receptor protein, that human fibroblasts have an average of
-2 x 10 5 molecules ofreceptor per cell . The reported number
of receptors per cell based on 1251-EGF binding capacity is - 1
x 105 receptors forhuman fibroblasts (3) . Our data, therefore,
may suggest the presence ofslightly more EGF receptors than
can detected by binding assays . Given the limitations in
precision of each method for determining receptor number,
however, we do not interpret the difference as evidence of an
intracellular pool ofEGF receptors .
Our data indicate that the basal rate of EGF receptor
turnover has a half-life of-10 h in human fibroblasts . Fibro-
blasts would, in the absence of added EGF, degrade EGF
receptors at a rate of -10,000 receptors per cell per hour.
When exogenous EGF was added, there was an immediate
increase in the rate ofEGF receptor degradation. The relative
magnitude of this change was approximately 8 .3-fold, indi-
cating the degradation of 85,000 receptors per cell per hour
immediately after the addition ofEGF.
The data presented in this report are difficult to reconcile
with recycling or inactivation of the EGF receptor during
down regulation . Rather, the clearest interpretation is that
EGF receptors are rapidly degraded in the presence ofEGF.
We cannot, however, from these data determine whetherthere
is a one to one stoichiometry between ligand degradation and
receptor degradation . It is interesting, however, that the pub-
lished data for the degradation of '25I-EGF indicate that it has
a half-life of- 1 h in human fibroblasts (3), equivalent to that
calculated for the EGF-accelerated turnover of the receptor
in these studies.
The speed of the EGF-induced accelerated receptor degra-
dation was not anticipated . Although we have observed ac-
celerated receptor degradation within 5-10 min, published
data show that "I-EGF degradation (as measured by the
appearance of degradation products) is not detectable in the
first 15 min. Two alternative explanations can be offered for
this discrepancy. EGF is reported to bind to surface receptors
and very rapidly induce their internalization (35). Internali-
zation of the ligand should easily occur within the time that
we have observed stimulated degradation of the receptor.
Once internalized, thehormone is localized within the lumen
of an endocytic vesicle and is segregated from the cell cyto-
plasm. The EGF receptor, however, is most likely a trans-
membrane protein and would, at least in part, be exposed to
the cell cytoplasm . At this point preferential degradation of
the receptor by cytoplasmic enzymes could occur.
Alternatively, the EGF receptor may simply be more sen-
sitive to lysosomal enzymes than EGF and for that reason
degraded more quickly . The morphological data of Gorden
et al . (14) demonstrate that when 12Sí-EGF is added tohuman
fibroblasts at 37°C, autoradiographic grains begin to accu-
mulate in the lysosomal compartment after 2 min . It would
appear, therefore, that both EGF and its receptor reach the
lysosome within the times that we have observed receptor
degradation . That EGF-accelerated receptor degradation oc-
curs within lysosomes is indicated by the fact that either
methylamine and chloroquine, lysosomotropic agents that areroutinely employed to block EGF degradation (12), or con-
ditions that interfere with the movement of endosomes, i.e.,
monensin or reduced (25°C) temperature, inhibited receptor
degradation.
Although the significance of EGF-receptor internalization
and degradation to the production of cellular responses to the
hormone is not clear, the degradation ofthe receptor has one
definite consequence for the mitogenic activity of EGF. Data
from our laboratory (36, 37) and others (38) have shown that
EGF must remain in the medium and be able to bind to
surface receptors in a continuous fashion for at least 6 to 8 h
before quiescent cells are committed to enter the S phase of
the cell cycle. Since EGF receptors are rapidly degraded in
the presence ofEGF, there would seem to exista requirement
for the constant synthesis of new EGF receptors to replace
those that are degraded. Continuous receptor synthesis would
be required for 6 to 8 h after EGF addition for stimulation of
DNA synthesis to occur. It has been recognized for some time
that continuous protein synthesis is necessary for quiescent
cells to become proliferative (39). Our data would indicate
that the synthesis of specific membrane receptors constitutes
part of this requirement.
The EGF receptor is, by several experimental approaches,
a glycoprotein that contains not only a ligand binding site,
but also a tyrosine-specific protein kinase activity that is
activated by EGF binding. In view of the intrinsic association
of this kinase activity with the receptor, the production of
lower molecular weight degradation products during receptor
turnover would be of interest. However, we do not detect any
degradation intermediates. Putative degradation products at
very low levels were detected in studies utilizing covalent "SI-
EGF-receptor complexes (20-21). Of course our assay will
only detect fragments that are antigenically recognized by the
antibodies we have employed. Proteolytic fragments of the
EGF receptor, produced by papain treatment in vitro, as
small as 45,000 daltons were recognized by these antisera
(unpublished data). Although these antisera do recognize the
'251-EGF binding site as well as other surface-exposed portions
of the receptor, we do not know whether they detect the
protein kinase domain (26).
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